KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations (2018 - 2025)

Esperion Therapeutics' Income from Continuing Operations history spans 8 years, with the latest figure at 62597000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 315.28% year-over-year to 62597000.0; the TTM value through Dec 2025 reached 24331000.0, down 85.96%, while the annual FY2025 figure was 22641000.0, 56.25% up from the prior year.
  • Income from Continuing Operations reached 62597000.0 in Q4 2025 per ESPR's latest filing, up from 32010000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 62597000.0 in Q4 2025 to a low of 90949000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 38067400.0, with a median of 47636000.0 recorded in 2021.
  • The largest YoY upside for Income from Continuing Operations was 315.28% in 2025 against a maximum downside of 171.3% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 69058000.0 in 2021, then rose by 17.69% to 56842000.0 in 2022, then decreased by 1.02% to 57424000.0 in 2023, then soared by 49.36% to 29077000.0 in 2024, then soared by 315.28% to 62597000.0 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Income from Continuing Operations are 62597000.0 (Q4 2025), 32010000.0 (Q3 2025), and 13391000.0 (Q2 2025).